X4 pharmaceuticals, inc (ASNS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-

-

-

-

-

-11,282

-8,602

-20,768

7,367

-

-

-

-

Net loss

-11,138

-

-

-

-10,873

-

-

-

-

-

-11,600

-5,705

-5,385

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

613

664

691

433

262

288

198

145

128

-135

273

172

182

Depreciation and amortization expense

36

32

27

24

20

26

26

25

26

-77

52

48

48

Non-cash lease expense

158

153

172

125

119

-

-

-

-

-

-

-

-

Accretion of debt discount

119

111

215

216

153

72

21

32

27

-1,418

198

436

941

Non-cash rent expense

-

-

-

-

-

-

-

-

-

-

-6

-6

-5

Loss on extinguishment of debt

-162

-

-

-

0

-

-

-

-

-

-

-

-

Change in fair value of preferred stock warrant liability

0

-183

0

0

288

3,223

-45

-283

592

-

-

-

-

Change in fair value of derivative liability

0

-

0

0

183

-

-5

159

-565

-

0

0

762

Other

-70

-

-

-

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

3,000

-

-

-

0

-

-

-

-

-

-

-

-

Grant and incentive receivables

-

-

-

-

-

-

-

-

-

-

604

-12

-535

Prepaid expenses, other current assets and research and development incentive receivable

869

181

-277

-608

595

352

-141

-320

-170

556

-2,666

-244

1,952

Accounts payable

-800

379

-1,429

-3,034

1,332

1,098

814

-42

-563

-3,511

2,905

-1,902

1,339

Accrued expenses

-668

755

562

915

-2,072

375

721

213

240

-654

629

290

1,144

Lease liabilities

-210

-213

-143

-196

-201

-

-

-

-

-

-

-

-

Unearned income

-

-

-

-

-

-

-

-

-

-

-806

-379

1,474

Net cash used in operating activities

-15,527

-9,241

-12,772

-14,292

-11,750

-6,734

-6,721

-5,783

-6,182

-

-

-

-

Cash flows from investing activities:
Cash, cash equivalents and restricted cash acquired in connection with the Merger

0

-

0

0

-26,406

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-3,511

Acquisition of property, equipment and intangible assets

555

83

81

10

0

-

-

-

-

319

18

24

17

Net cash provided by investing activities

-555

21

815

-10

26,406

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from exercise of stock options and warrants

96

187

40

452

113

-

-

-

-

-

-

-

-

Proceeds from borrowings under loan and security agreements, net of issuance costs

4,888

-

0

9,849

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-17

Proceeds from issuance of Series B convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

22,478

0

0

4,935

Repurchase of Series Seed convertible preferred stock

-

-

-

-

-

0

-34

34

1,126

-

-

-

-

Repayments of borrowings under loan and security agreement

-

-

-

-

-

4,880

500

500

500

-1,750

585

583

582

Payments of issuance costs of convertible promissory notes

-

-

-

-

-

-

-

-

-

-

0

0

17

Payments of issuance costs of convertible preferred stock

-

-

-

-

-

-

-

-

34

-

-

-

-

Net cash provided by financing activities

4,984

60,284

-6,414

86,678

113

5,028

3,995

-493

-1,660

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

4,336

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-34

16

-264

19

-21

-

-

-

-

-402

347

43

12

Net (decrease) increase in cash, cash equivalents and restricted cash

-11,132

51,080

-18,635

72,395

14,748

-1,706

-2,726

-6,276

-7,842

-16,560

-1,122

28,595

820

Supplemental disclosure of cash flow information
Cash paid for interest

-

-

-

-

-

-

-

-

146

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Issuance costs not yet paid

20

-

-

-

0

-

-

-

-

-

-

-

-

Conversion of convertible preferred stock into common stock

0

-

0

0

64,675

-

-

-

-

-

-

-

-

Conversion of redeemable common stock into common stock

0

0

0

0

734

-

-

-

-

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

19

Derivative liability in connection with issuance of convertible promissory notes

-

-

-

-

-

-

-

-

-

-

0

0

403

Conversion of convertible preferred stock warrants into common stock warrants

0

-

0

0

5,235

-

-

-

-

-

-

-

-

Fair value of net assets acquired in the Merger

0

-26,406

0

0

46,358

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

16

13

7